Nova Biomedical Enhances Integrated Workflows with NanoCellect Acquisition for Cell Line Development

Nova Biomedical Expands Integrated Workflows with NanoCellect Products

Nova Biomedical has recently announced its acquisition of certain assets from NanoCellect, a provider of microfluidic technology for cell sorting. This strategic move is set to enhance Nova's capabilities in developing cell lines and strengthen its support for bio-pharmaceutical workflows from the early development phase through to production.

The acquisition introduces the NanoCellect® WOLF G2® platform for cell sorting, which utilizes a gentle, microfluidic-based approach for cell selection and isolation. This technology complements Nova Biomedical's existing Solentim portfolio, which focuses on clonal generation, verification, and growth analysis—creating a more integrated approach to cell line development. Together, these technologies streamline the processes of cell selection, isolation of single cells, and reliable clone verification.

By expanding its portfolio, Nova Biomedical aims to reduce the timeline required for cell line development and improve outcomes in clone selection. Furthermore, this integration lays a solid foundation for process development, scaling, and production.

In addition to the technologies acquired from NanoCellect, Nova Biomedical also offers robust analytical solutions for monitoring cell cultures, such as metabolite analysis with BioProfile® FLEX2, osmolality measurements using OsmoTECH®, and cell counting and viability assessments with BioProfile® FAST CDV. These capabilities serve as essential checkpoints within the entire bioprocessing framework, utilized from development all the way through to production.

John Luck, the President of Nova Biomedical's Biopharma Business, stated, "NanoCellect adds a critical upstream capability to our portfolio, enhancing our ability to interconnect key steps in cell line development. By merging cell sorting with clone isolation and extremely reliable clone verification, along with analytical checkpoints such as monitoring cell cultures and osmolality measurements, our customers can achieve successful clones and generate insights that optimize clone selections and improve outcomes during process development, scaling, and production. This is a significant step in creating a more integrated and distinctive platform for cell line development and bioprocessing."

About Nova Biomedical

Nova Biomedical stands as a global innovator, providing advanced analytical instruments and solutions tailored for the bio-pharmaceutical and clinical markets. The company's array of products supports crucial workflows for cell line development, process enhancement, and production, enabling clients to enhance productivity, quality, and operational efficiency.

About NanoCellect

NanoCellect specializes in developing microfluidic technologies for cell sorting, allowing for soft and sterile isolation of cells. Their platforms are utilized in applications ranging from cell line development to single-cell analysis and research in cellular therapies.

In conclusion, the addition of NanoCellect products marks a pivotal enhancement in Nova Biomedical's commitment to foster an integrated portfolio of technologies. This will not only support continuity in bioprocessing but also provide critical insights into decision-making throughout the development cycle, enhancing efficiency and outcomes in cell line development.